603716 Stock Overview
Provides intensive operation services of medical inspection in China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Thalys Medical Technology Group Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥5.88 |
52 Week High | CN¥13.10 |
52 Week Low | CN¥5.13 |
Beta | 0.71 |
11 Month Change | -17.53% |
3 Month Change | -2.00% |
1 Year Change | -47.03% |
33 Year Change | -48.42% |
5 Year Change | -66.78% |
Change since IPO | -46.89% |
Recent News & Updates
Shareholder Returns
603716 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -1.3% | 0.4% | -0.6% |
1Y | -47.0% | -24.5% | -21.3% |
Return vs Industry: 603716 underperformed the CN Biotechs industry which returned -24.5% over the past year.
Return vs Market: 603716 underperformed the CN Market which returned -21.3% over the past year.
Price Volatility
603716 volatility | |
---|---|
603716 Average Weekly Movement | 10.4% |
Biotechs Industry Average Movement | 6.0% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 603716's share price has been volatile over the past 3 months.
Volatility Over Time: 603716's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 1,406 | Zheng Wang | www.thalys.net.cn |
Thalys Medical Technology Group Corporation provides intensive operation services of medical inspection in China. The company was formerly known as Thalys Medical Technology Inc. and changed its name to Thalys Medical Technology Group Inc. in September 2020. Thalys Medical Technology Group Inc. was founded in 2004 and is headquartered in Wuhan, China.
Thalys Medical Technology Group Corporation Fundamentals Summary
603716 fundamental statistics | |
---|---|
Market cap | CN¥1.09b |
Earnings (TTM) | -CN¥140.51m |
Revenue (TTM) | CN¥2.05b |
0.5x
P/S Ratio-7.9x
P/E RatioIs 603716 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603716 income statement (TTM) | |
---|---|
Revenue | CN¥2.05b |
Cost of Revenue | CN¥1.65b |
Gross Profit | CN¥400.73m |
Other Expenses | CN¥541.24m |
Earnings | -CN¥140.51m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.74 |
Gross Margin | 19.57% |
Net Profit Margin | -6.86% |
Debt/Equity Ratio | 79.7% |
How did 603716 perform over the long term?
See historical performance and comparison